Plain-English translation of NCT03543839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Erythematosus, Systemic research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether , an FDA-approved medication that works by reducing certain immune cells, can help people with newly diagnosed lupus if started early. The study involves weekly self-injections over two years and will measure whether the medication reduces harmful immune activity, prevents disease flares, and helps patients reach remission.
Research shows that lupus-related immune problems can begin years before symptoms appear, and treating the disease early may prevent serious organ damage and long-term complications. This trial tests whether starting this medication right after diagnosis—rather than waiting—could change the course of the disease.
You likely qualify if…
You likely don't qualify if…
You will give yourself a 200mg injection under the skin once per week for the entire 2-year study. You will be randomly assigned to receive either the active medication, the active medication for 1 year followed by placebo for 1 year, or placebo for the full 2 years. Throughout the study, you'll have blood tests to check your immune system, disease activity, and overall health, and you'll be monitored for any lupus flares or side effects.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States